Faron Pharmaceuticals Oy (FARN.L)
GBp 175.0
(2.94%)
GBp 175.0
(2.94%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 19 Thousand |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | 19 Thousand |
| Operating Expenses | 28.56 Million | 27.42 Million | 21.1 Million | 16.65 Million | 13.1 Million | 19.67 Million |
| Selling, General and Administrative Expenses | 9.05 Million | 7.49 Million | 9.87 Million | 4.89 Million | 3.04 Million | 3.75 Million |
| Research and Development Expenses | 19.54 Million | 20.73 Million | 17.36 Million | 13.87 Million | 10.23 Million | 16.03 Million |
| Other Expenses | -26 Thousand | -803 Thousand | -6.13 Million | -2.12 Million | -185 Thousand | 1.22 Million |
| Cost and Expenses | 28.56 Million | 27.42 Million | 21.1 Million | 16.65 Million | 13.1 Million | 19.67 Million |
| Operating Income | -28.56 Million | -27.42 Million | -21.1 Million | -16.65 Million | -13.1 Million | -19.98 Million |
| Interest Expense | - | 1.4 Million | 235 Thousand | 389 Thousand | 224 Thousand | 121 Thousand |
| Income Tax Expense | - | 1.3 Million | 16 Thousand | 10 Thousand | 11 Thousand | 2000.00 |
| Earnings before Tax | -30.94 Million | -28.73 Million | -21.17 Million | -16.93 Million | -13.25 Million | -20.08 Million |
| Net Income | -30.94 Million | -30.03 Million | -21.19 Million | -16.94 Million | -13.26 Million | -20.08 Million |
| Earnings Per Share Basic | -449.84 | -499.69 | -408.89 | -361.78 | -332.54 | -626.96 |
| Earnings Per Share Diluted | -449.84 | -499.69 | -408.90 | -361.78 | -332.54 | -626.96 |
| Weighted Average Shares Outstanding | 68.78 Thousand | 60.1 Thousand | 51.83 Thousand | 46.84 Thousand | 39.88 Thousand | 32.03 Thousand |
| Weighted Average Shares Outstanding (Diluted) | 68.78 Thousand | 60.1 Thousand | 51.83 Thousand | 46.84 Thousand | 39.88 Thousand | 32.03 Thousand |
| Gross Margin | - | - | - | - | - | 1.00 |
| EBIT Margin | - | - | - | - | - | -1027.63 |
| Profit Margin | - | - | - | - | - | -1057.16 |
| EBITDA | -28.37 Million | -27.05 Million | -20.65 Million | -16.5 Million | -12.78 Million | -19.86 Million |
| Earnings Before Tax Margin | - | - | - | - | - | -1052.05 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | 149.52 Thousand |
| Gross Profit | - | - | - | - | - | -149.52 Thousand |
| Operating Expenses | 5645.00 | 5645.00 | 7878.00 | 29 Million | 8097.50 | 6406.00 |
| Selling, General and Administrative Expenses | 2314.00 | 2314.00 | 2379.00 | - | 2379.00 | 2147.00 |
| Research and Development Expenses | 3331.00 | 3331.00 | 5512.00 | - | 5512.00 | 4259.00 |
| Other Expenses | - | - | -13.00 | - | - | - |
| Cost and Expenses | 5645.00 | 5645.00 | 7878.00 | 29 Million | 8097.50 | 6406.00 |
| Operating Income | -5645.00 | -5645.00 | -7878.00 | -28.56 Million | -7878.00 | -6406.00 |
| Interest Expense | - | - | - | - | - | 788.85 Thousand |
| Income Tax Expense | 23.00 | 23.00 | - | - | - | 1.00 |
| Earnings before Tax | -7174.50 | -7174.50 | -8607.00 | -30.94 Million | -8607.00 | -6865.00 |
| Net Income | -7197.50 | -7197.50 | -8607.00 | -30.94 Million | -8607.00 | -6865.00 |
| Earnings Per Share Basic | -0.10 | -0.10 | -0.13 | - | -0.13 | -0.11 |
| Earnings Per Share Diluted | -0.10 | -0.10 | -0.13 | - | -0.13 | -0.11 |
| Weighted Average Shares Outstanding | 70.45 Thousand | 70.45 Thousand | 67.12 Thousand | 65.05 Million | 67.12 Thousand | 62.98 Thousand |
| Weighted Average Shares Outstanding (Diluted) | 70.45 Thousand | 70.45 Thousand | 67.12 Thousand | 65.05 Million | 67.12 Thousand | 62.98 Thousand |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -5566.00 | -5566.00 | -7866.50 | - | -7866.50 | -6319.00 |
| Earnings Before Tax Margin | - | - | - | - | - | - |
BLMN
NARMADA
PEN
ECLERX
0JCB
ALTN